Biogen (BUE:BIIB) Operating Cash Flow per Share

: ARS1,658.15 (TTM As of Mar. 2023)

View and export this data going back to 2019. Start your Free Trial

Biogen's operating cash flow per share for the three months ended in Mar. 2023 was ARS619.45. Biogen's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2023 was ARS1,658.15.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Biogen was -43.40% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -36.90% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -13.50% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 8.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Biogen's Operating Cash Flow per Share or its related term are showing as below:

BUE:BIIB' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -36.9 Med: 20.9 Max: 203.4
Current: -36.9

During the past 13 years, Biogen's highest 3-Year average Operating Cash Flow per Share Growth Rate was 203.40% per year. The lowest was -36.90% per year. And the median was 20.90% per year.

BUE:BIIB's 3-Year OCF Growth Rate is ranked worse than
91.8% of 805 companies
in the Drug Manufacturers industry
Industry Median: 10.80 vs BUE:BIIB: -36.90

Biogen Operating Cash Flow per Share Historical Data

The historical data trend for Biogen's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Operating Cash Flow per Share

1,136.42

2,257.81

2,134.04

2,457.18

1,589.58

Biogen Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Operating Cash Flow per Share																117.70	606.18	634.30	-201.78	619.45

Biogen Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Biogen's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2022 is calculated as

Operating Cash Flow per Share (A: Dec. 2022 )	=	Cash Flow from Operations (A: Dec. 2022 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2022 )
	=	232077.889	/	146.000
	=	1,589.57

Biogen's Operating Cash Flow per Share for the quarter that ended in Dec. 2022 is calculated as

Operating Cash Flow per Share (Q: Mar. 2023 )	=	Cash Flow from Operations (Q: Mar. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2023 )
	=	89944.517	/	145.200
	=	619.45

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS1,658.15

Biogen Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Biogen's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (BUE:BIIB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BUE:BIIB) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico IDP:Germany BIIB34:Brazil BIIB:Austria

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

http://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.